Anti-HIF-1 alpha antibody [EPR16897-145] - BSA and Azide free,Abcam,AB308434
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Human, Mouse
Application
Flow Cyt (Intra), IP, ChIC/CUT&RUN-seq, ChIP, WB, ICC/IF, ChIP-seq
Platform ID
BAB392866949
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data The protein expressed by the gene HIF1A functions as a master transcriptional regulator of the adaptive response to hypoxia, activating the transcription of over 40 genes under hypoxic conditions, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and others. These genes' protein products enhance oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF1A is crucial for embryonic vascularization, tumor angiogenesis, and ischemic disease pathophysiology. Its activation requires transcriptional coactivators like CREBBP and EP300, with activity enhanced by interactions with NCOA1 and/or NCOA2. Interaction with redox regulatory protein APEX1 activates CTAD and enhances activation by NCOA1 and CREBBP. Additionally, HIF1A is involved in axonal distribution and mitochondrial transport in neurons during hypoxia. In the context of microbial infection, specifically human coronavirus SARS-CoV-2, HIF1A is necessary for glycolysis induction in monocytes, leading to a proinflammatory state, inducing expression of ACE2, cytokines, and promoting virus replication and monocyte inflammatory response. This supplementary information is collated from multiple sources and compiled automatically. See full target information HIF1A
Category Paths
Please provide the required information below so that we can quickly source your products.